CPHN CPH Group AG
CPH Group AG, together with its subsidiaries, develops, manufactures, and distributes chemical products and packaging solutions for pharmaceutical customers in Europe, Asia, and North and South America. It operates through two segments: Zeochem and Perlen Packaging. The Zeochem segment produces molecular sieves for industrial and medical applications, chromatography gels for the pharmaceutical industry, and deuterated products used in analytics, pharmaceuticals, and OLED displays. This segment also operates production facilities in Switzerland, Bosnia and Herzegovina, the USA, Canada, China, and India. The Perlen Packaging segment focuses on the pharmaceutical industry, supplying coated plastic films used primarily in blister packaging to protect medications, as well as vials and containers for medical use; and PVC mono films and coated PVdC barrier films for use in the pharmaceutical industry. CPH Group AG was founded in 1818 and is based in Perlen, Switzerland.…
Industry Peers
Paper & Paper ProductsKey Statistics
About CPH Group (SWX: CPHN)
›
CPH Group (SWX: CPHN) is listed on the SIX Swiss Exchange, where its shares trade in CHF. It belongs to the Paper & Paper Products industry, part of the Basic Materials sector, and reports about 1,249 employees.
The shares were at 58.80 CHF on 20 November 2026, down 10.2% over 52 weeks. Its 52-week range is 54.20 CHF to 71.40 CHF: the price is 17.6% below the high and 8.5% above the low.
At a market capitalisation of 353.71M CHF, it trades at 17.2 times trailing earnings and 12.0 times forward earnings. The median trailing P/E of its 15 largest Paper & Paper Products peers is 21.0, a discount of 18% for CPHN. It pays a dividend yielding 3.46% (it pays out 58% of its earnings), against a median of 3.25% among the dividend payers in that peer group.
CPH Group reports return on equity of 11.5%, an operating margin of 8.9% and flat revenue year over year.
Its debt exceeds its cash by 25.44M CHF, a debt-to-equity ratio of 0.26. Its Piotroski F-score is 6 out of 9, an average reading of its financial health. 2 analysts cover the stock, with an average rating of Buy; their mean price target of 78.50 CHF is 33.5% above the current price.